American biopharmaceutical company in Cambridge, Massachusetts, spun out of Ironwood Pharmaceuticals in 2019 and listed on the Nasdaq, which works on soluble guanylate cyclase stimulators. Develops small molecules that act on the nitric oxide signalling pathway for serious central nervous system and other diseases, with its lead compound zagociguat studied in mitochondrial disease and cognitive impairment, and runs its own clinical development.
No hay comentarios disponibles.
Deja tu valoración & comentario